Skip to main content
Signal8

ACCURAY INC (ARAY)

Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Accuray Incorporated logo

Accuray Incorporated

NASDAQ:ARAYHealthcare
+0.00%$0.1400
AH$0.1373-1.93%vs close
Mkt Cap$16.72M
Float116.67M
O/S119.44M
Vol
$ Vol
RVOL
Inst Own59.7%
Earnings
Dilution
Phase Distribution
6 lead-sponsored trials·0 active·2 completed
Phase 22
Phase 31
Not applicable3
(7 more as collaborator)
Status Overview
Completed2
Stopped3
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Withdrawn

    Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

    Transarterial Chemoembolization, CyberKnife SBRT

    Recurrent Hepatocellular Carcinoma

    Enrollment
    0
    Start
    Feb 2011
    Primary Completion
    Feb 2014est.
    Completion
    Feb 2016est.
    NCT01318200
  • Phase 2
    Unknown status

    CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

    CyberKnife Stereotactic Radiosurgery

    Non-small Cell Lung Cancer

    Enrollment
    40
    Start
    Apr 2006
    Primary Completion
    Dec 2021est.
    Completion
    Dec 2021est.
    NCT00643318
  • Phase 2
    Terminated

    CyberKnife® for Hepatic Metastases From Colorectal Cancer

    CyberKnife SBRT

    Colorectal Liver Metastases

    Enrollment
    15
    Start
    Jan 2011
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT01318447
  • Not applicable
    Completed

    CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

    CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk

    Prostate Cancer, Prostatic Cancer +3

    Enrollment
    307
    Start
    Oct 2007
    Primary Completion
    Apr 2022
    Completion
    Apr 2022
    NCT00643617
  • Not applicable
    Completed

    CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution

    CyberKnife Stereotactic Radiosurgery

    Prostate Cancer, Prostatic Cancer +3

    Enrollment
    379
    Start
    Dec 2007
    Primary Completion
    Jan 2021
    Completion
    Jan 2021
    NCT00643994
  • Not applicable
    Terminated

    Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

    CyberKnife Stereotactic Radiotherapy, Surgery

    Non-small Cell Lung Cancer

    Enrollment
    36
    Start
    Dec 2008
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT00840749